Biogen’s stock rises after E.U. regulator reverses negative view of ...
10 hours ago · SPX. -0.27%. Biogen Inc.’s stock rose 1% Thursday, after Europe’s pharmaceutical regulator issued a positive opinion on the Alzheimer’s disease drug that the company developed with Japanese ...
European committee takes a second look at ... - Associated Press News
9 hours ago · A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting the drug.. Biogen said Thursday that the drug, known in the U.S. as Leqembi, received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use as a treatment for early Alzheimer’s disease.
EU drugs regulator recommends Alzheimer's drug from Eisai-Biogen
12 hours ago · Nov 14 (Reuters) - The European Union's drugs regulator on Thursday said it recommends approval of Eisai (4523.T), opens new tab and Biogen's (BIIB.O), opens new tab Leqembi in patients with early ...
European regulators now recommend Alzheimer’s treatment …
11 hours ago · Nov. 14, 2024. Europe Correspondent. LONDON — Reversing an earlier decision, European regulators on Thursday recommended that an Alzheimer’s therapy from Eisai and Biogen should be approved ...
Biogen to Realign Resources for Alzheimer's Disease Franchise
CAMBRIDGE, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced plans to reprioritize its resources in Alzheimer’s disease (AD), a strategic therapeutic area expected to drive near and long-term growth.
Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, …
Feb 23, 2024 · SOD1 -ALS is a devastating, uniformly fatal, and ultra-rare genetic form of ALS affecting less than 1,000 people in Europe 1. With QALSODY, Biogen has advanced the role of neurofilament in the development of new medicines for ALS, with the potential to accelerate further discovery in the field.
Biogen and Neomorph Announce Multi-Target Research …
CAMBRIDGE, Mass. and SAN DIEGO, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Neomorph Inc. announced a research collaboration to discover and develop molecular glue degraders for priority targets in Alzheimer’s, …
Biogen (BIIB) Raises Forecast as Alzheimer’s Drug Leqembi Shows …
Oct 30, 2024 · Biogen Inc. raised its annual earnings guidance after reporting better-than-expected third-quarter sales and profit, driven by ongoing cost-cutting measures and the strong performance of its new...
Biogen gains as Eisai wins EU nod for Alzheimer’s drug - MSN
Biogen (NASDAQ:BIIB) shares traded higher on Thursday after an expert panel of the EU drug regulator, the European Medicines Agency (EMA), endorsed Leqembi (lecanemab), the FDA-approved Alzheimer ...
Ticker: Biogen Alzheimer's drug gets second look in EU; Ford takes ...
7 hours ago · Ford takes $165M hit on slow recall. Ford Motor Co. will pay a penalty of up to $165 million to the U.S. government for moving too slowly on a recall and failing to give accurate recall ...
- Some results have been removed